aTyr Pharma Inc (LIFE)
0.3737
-0.00 -0.35%
NASDAQ
Jun 26, 16:59
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -0.98 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -29.98M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 17.14M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | -- |
| PE Ratio (TTM) | -- |
| Price to Book Value | 0.5814 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -6.033M |
| Return on Equity (TTM) | Upgrade |
View All LIFE News
News
-
WireHeadlineTime (ET)
-
Yahoo05/27 15:41
-
MT Newswires05/22 14:24
-
SA Breaking News05/22 07:27
-
MT Newswires05/13 16:54
-
Yahoo05/13 16:27
-
SA Breaking News05/13 16:09
-
Globe Newswire05/13 16:05
-
Globe Newswire05/06 16:58
-
Globe Newswire04/16 08:00
-
MT Newswires04/11 11:54
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 03/19/2019 17:00 EDT | Misc | aTyr Pharma Inc Fourth Quarter Earnings Conference Call in 2018 |
| 08/10/2018 | Earnings | aTyr Pharma Inc Second Quarter Earnings Results in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.atyrpharma.com
- Investor Relations URL: http://atyrpharma.investorroom.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Aug. 10, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: aTyr Pharma Inc is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Business activity is primarily conducted through the United States.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 0.3737 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Excel Add-In Codes
- Name: =YCI("LIFE","name")
- Description: =YCI("LIFE","description")
- Sector: =YCI("LIFE","sector")
- Industry: =YCI("LIFE","industry")
- Est. Current Fiscal Year End: =YCI("LIFE","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- LIFE Tweets Stocktwits
Advertisement
